ArcherDX Enters Collaboration with Bristol Myers Squibb to Apply Personalized Cancer Monitoring (PCMâ„¢) to Clinical Research Aims to Inform use of Minimal Residual Disease (MRD) […]

ArcherDX Announces Strategic Collaboration with AstraZeneca to Develop Personalized Cancer Monitoring (PCM) Assays for Minimal Residual Disease (MRD) AstraZeneca to Leverage ArcherDX’s PCM Liquid Biopsy […]

ArcherDX Receives Breakthrough Device Designation to Detect NTRK Gene Fusions BOULDER, Colo., May 19, 2020 /PRNewswire/ — ArcherDX, Inc. today announced that the U.S. Food […]

Bayer and ArcherDX Announce Global Collaboration to Develop Next-Generation Sequencing (NGS)-based Companion Diagnostic (CDx) for VITRAKVI® (larotrectinib) Collaboration will focus on development of a companion […]

ArcherDX Appoints Jason Ryan to Board of Directors BOULDER, Colo., May 7, 2020 /PRNewswire/ — ArcherDX, Inc. today announced the appointment of Jason Ryan, Chief […]

ArcherDX and UCL Present New Minimal Residual Disease Surveillance Data from their Collaboration at 2020 AACR Virtual Annual Meeting First presentation of the data utilizing […]

ArcherDX and Premier Inc. Partner to Deliver Personalized Genomic Testing to Patients STRATAFIDEâ„¢ Proprietary Test Designed to Enable Community Hospitals to Rapidly Deliver Accurate and […]

Letter from Chief Executive Officer and Co-founder, Jason Myers April 17, 2020 Over the course of the last several weeks, our lives have been disrupted […]